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Summary: Background: Rheolytic thrombectomy (RT) for acute iliofemoral deep vein thrombosis (DVT) with ﬁ rst-generation 
techniques is often incomplete and adjunctive conventional catheter-directed thrombolysis (CDT) is required in more than 
half of patients to achieve venous patency. Patients and methods: From the prospective Bern Venous Stent Registry, we inves-
tigated rates of primary treatment success, primary patency, and post-thrombotic syndrome (PTS) from 40 consecutive pa-
tients (mean age 51 ± 19 years, 45 % women) with acute iliofemoral DVT, treated with a novel directional RT technology and 
stent placement. Overall, 24 patients were treated for native-vessel iliofemoral DVT (11 with single-session RT, 13 with bail-
out RT after failed CDT) and 16 for iliofemoral stent thrombosis. Pulse-spray thrombolysis (r-tPA 10 mg) was performed in 29 
(73 %) patients. The mean follow-up duration was 193 ± 132 days (minimum 90 days). Results: Overall, primary treatment 
success of RT was 95 %; only two patients required adjunctive CDT to restore patency. In 24 patients with native-vessel DVT, 
six-month primary patency was 92 % (95 %CI 75–99 %), and 23 patients (96 %) were free from the PTS according to the Vil-
lalta score. In 16 patients with stent thrombosis, six-month primary patency was 63 % (95 %CI 35–85 %) and 50 % were free 
from PTS. Except for transient macroscopic haemoglobinuria in all patients, no other side effects were recorded. Conclusions: 
In patients with iliofemoral DVT of native or stented vessels, RT followed by stent placement appears to be effective and safe. 
The novel technique enables single-session DVT treatment in the majority of patients without the need for prolonged CDT.
Keywords: Iliofemoral deep vein thrombosis, post-thrombotic syndrome, rheolytic thrombectomy, catheter-directed throm-
bolysis, AngioJet ZelanteDVT
in a fi rst session, prolonged monitoring in the intermedi-
ate care unit during the administration of local throm-
bolysis, and venography with provisional stent placement 
in a second session.
In recent years, a trend emerged to complete the DVT 
revascularization and stent placement procedure in a sin-
gle session. Rheolytic thrombectomy (RT) uses the Ven-
turi-Bernoulli eff ect (negative pressure induced by fast 
fl owing saline jets) and enables single-session DVT thera-
py [12]. Rheolytic thrombectomy can be combined with 
adjunctive local administration of a high-pressure throm-
bolysis spray (PowerPuls®) to facilitate thrombus remov-
al. In the Peripheral Use of AngioJet Rheolytic Thrombec-
tomy with a Variety of Catheter Lengths (PEARL) study 
of 329 DVT patients, RT with a fi rst-generation system 
(AngioJet® 6F, Boston Scientifi c, Maple Grove, MN, USA) 
was eff ective and safe [13]. However, 61 % of the PEARL 
Introduction
Acute iliofemoral deep vein thrombosis (DVT) is a major 
cause for morbidity, as approximately half of the patients 
managed conservatively with anticoagulation therapy and 
compression stockings develop the post-thrombotic syn-
drome (PTS) [1–4]. The residual thrombus load correlates 
with the probability of a future PTS [5, 6]. The degree of 
the PTS correlates with impairment of quality of life [7, 8].
As compared to conservative therapy, catheter-direct-
ed thrombolysis (CDT) is associated with greater venous 
patency and reduced risk of PTS at two years [9]. Interna-
tional consensus guidelines recommend CDT with provi-
sional stent placement of the underlying venous outfl ow 
obstruction for selected patients with acute iliofemoral 
DVT [10, 11]. However, CDT with provisional stent place-
ment is complex because it involves catheter placement 
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patients required adjunctive CDT to restore venous pa-
tency. The Angiojet ZelanteDVT® catheter (Boston Scien-
tifi c, Maple Grove, MN, USA) is a novel 8-French RT sys-
tem specifi cally designed for single-session treatment of 
acute iliofemoral DVT.
The aim of the present study was to investigate patency 
rates and early clinical outcomes of patients with acute 
iliofemoral DVT treated with the Angiojet ZelanteDVT® 
system.
Patients and methods
Study design
The current analysis was derived from the Bern Venous 
Stent Registry, an ongoing study that consecutively enrols 
patients who received venous stents at the University Clin-
ic of Angiology in Bern, Switzerland, since 1 January 2008. 
From this registry we included all patients with least 90 
days of follow-up, who underwent AngioJet ZelanteDVT® 
for acute iliofemoral DVT or iliofemoral venous stent 
thrombosis since market introduction in December 2015. 
Exclusion criteria for registry enrolment are the inability to 
provide informed consent, age below 18 years, or estimat-
ed life expectancy < 3 months.
The registry and participant consent form were ap-
proved by the Swiss Ethics Committee on research involv-
ing humans. The study is registered on the National Insti-
tutes of Health website (ClinicalTrials.gov; identifi er 
NCT02433054).
For all enrolled patients, baseline demographic infor-
mation (age, gender, weight, height, indication), comor-
bid conditions (concomitant pulmonary embolism, ac-
tive cancer or treatment, thrombophilia, hypertension), 
risk factors (smoking, hormonal therapy, previous DVT, 
immobility, recent surgery/trauma, May-Thurner com-
pression, obesity), and anticoagulant/antiplatelet therapy 
were recorded. Procedural data included type, diameter, 
length, and site of implanted stents. Venograms were 
used to analyse thrombus extension and primary treat-
ment success.
For this analysis we predefi ned three patient groups:
1. primary single-session RT for iliofemoral DVT of native 
vessels,
2. bail-out RT after incomplete or failed CDT for iliofemo-
ral DVT of native vessels,
3. primary single-session RT of DVT caused by iliofemoral 
venous stent thrombosis.
Study device
The Angiojet ZelanteDVT® (Boston Scientifi c, Marlbor-
ough, MA, USA) catheter is a novel RT device which has 
been specially designed for single-session treatment of ili-
ofemoral DVT (Figure 1).
Procedures
Iliofemoral DVT was objectively confi rmed by duplex ul-
trasound or contrast-enhanced computed tomography. All 
patients were initially treated with intravenous unfraction-
ated heparin, adjusted to target and partial thromboplastin 
time corresponding to therapeutic heparin levels was acti-
vated (equivalent to 0.3 to 0.7  U/mL by factor Xa inhibi-
tion). In patients with thrombus extension into the pop-
liteal veins, initial CDT was mainly performed as a fi rst 
thrombus removal strategy. Following popliteal access 
with a 10-French sheath, RT (AngioJet ZelanteDVT®) was 
performed using two thrombectomy passes of the throm-
botic occlusion by advancing the device by 2–3 millimetre 
per second. Each device activation run lasted no longer 
than 30 seconds with breaks of 30 seconds in between the 
runs to avoid arrhythmia. During the thrombectomy pro-
cedure, the rotation hub at the catheter shaft was rotated 
by 270 degrees back and forth to accomplish circumferen-
tial thrombus removal. If RT was incomplete, defi ned as 
absence of fl ow or residual thrombus with near complete 
vessel occlusion, an intraclot injection of 10  mg of r-tPA 
(total injected volume 30 millilitres) using the Power-
Pulse® technique was performed. After 20 Minutes dwell 
time, another two thrombectomy passes were performed 
as described above, not exceeding a total device activation 
time of 300 seconds. Diagnosis of an iliac vein compression 
syndrome or of residual post-thrombotic obstruction was 
established after successful thrombus removal by digital 
subtraction venography in two orthogonal views or by intra-
vascular ultrasound if venography was equivocal. Stenting 
was performed in the presence of a venous stenosis > 50 % 
by intravascular ultrasound or venography or in the pres-
ence of collateral fl ow, or in the absence of fl ow [14].
Depending on the aff ected venous segment and the 
presence or absence of a compression syndrome, the fol-
lowing stents were used: for the inferior vena cava Sinus-
XL® stent, for compressed iliac veins Sinus-Obliquus® May 
Thurner stent, for post-thrombotic iliac or common femo-
Figure 1. AngioJet ZelanteDVT® catheter.
Schematic drawing of the tip of the 8-French AngioJet ZelanteDVT® 
catheter (Boston Scientiﬁ c, Maple Grove, MN, USA). It is an isovolumet-
ric, directional, hydrodynamic thrombectomy device using accelerated 
reversed ﬂ uid, which runs through the inside of the catheter and pro-
vides a strong –600 mmHg suction (Venturi) effect at the catheter tip. 
The treatment segment with one larger proximal suction window and 
one smaller distal outﬂ ow window (arrows) can be identiﬁ ed under 
ﬂ uoroscopy through two marker bands. Between the marker bands is 
an eccentric middle marker, indicating the (opposite) direction of the 
inﬂ ow and outﬂ ow windows.
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ral veins Sinus-XL Flex® stent, and for the deep femoral 
vein Sinus-SuperFlex® stent (Optimed, Ettlingen, Germa-
ny). Stent diameters were 20–24 mm for the inferior vena 
cava, 14–16 mm for the iliac veins, 14 mm for the common 
femoral vein, and 12 mm for the deep femoral vein.
Following endovascular therapy, oral anticoagulation 
therapy was initiated. Patients received either vitamin K 
antagonists or direct oral anticoagulants (rivaroxaban, 
apixaban, or dabigatran).
Clinical follow-up
Clinical follow-up assessments with duplex sonography 
were performed in all patients at the vascular outpatient 
clinic by vascular specialists at the fi rst postintervention-
al day, at three, six, and 12 months. At each visit, signs 
and symptoms of post-thrombotic syndrome, including 
all points of the Villalta score [15] and the revised venous 
clinical severity score [16] were systematically examined 
by vascular specialists. Each stented venous segment was 
examined by ultrasound for (1) the presence or absence 
of thrombotic changes (thickening of the venous wall, in-
traluminal webs, intraluminal material) and (2) fl ow pat-
terns in treated segments to determine if they were mod-
ulated by the cardiac cycle, spontaneously modulated 
with respiration, or modulated with deep inspiration. 
Peak fl ow velocities [cm/sec] were recorded from the 
common femoral vein.
Deﬁ nition of outcomes
Primary treatment success was defi ned as antegrade fl ow 
and maximal luminal stenosis of 30 % assessed on the fi -
nal procedural venography and evidence of a spontaneous 
Doppler signal in the treated vein segment [17]. Primary 
patency rate was defi ned as the percentage of patients with 
primary treatment success and without the occurrence of 
either thrombosis of the treated segment or a reinterven-
tion to maintain patency of the treated segment. Resteno-
sis in the treated venous segment was defi ned by ultra-
sound as a luminal obstruction of > 50 % of the venous 
cross-sectional area in B-mode or deterioration of the 
Doppler fl ow pattern from the fi rst postinterventional day 
to the follow-up ultrasound study. This included an in-
crease of the peak fl ow velocity to > 1 m/s or a loss of res-
piratory modulation of fl ow.
Statistical analyses
Continuous baseline and outcome data were presented as 
mean ± standard deviations and were compared between 
the three groups, using one-way analysis of variance and 
Dunn’s multiple comparison tests. Categorical baseline 
and outcome data were analysed between the groups us-
ing the chi-square test. Kaplan-Meier survival analysis was 
used to estimate patency rates, which were reported with 
the 95 % confi dence interval. A log rank test was used to 
compare primary patency rates between patients with ili-
ofemoral DVT and patients with iliofemoral venous stent 
thrombosis. A p < 0.05 indicated statistical signifi cance. 
For data management and statistical analysis, we used the 
Prism® V5.0f statistical software package (GraphPad®, San 
Diego, CA, USA).
Results
Baseline characteristics
Overall, 40 patients (mean age 51 ± 19 years; 18 women) 
were treated with directional RT between December 
2015 and March 2017. During the observation period, fi ve 
patients with iliofemoral DVT were treated conservative-
ly. Baseline characteristics were similar in the groups ex-
cept for a history of previous DVT and hormonal therapy 
(Table I). Overall, 24 patients (60 %) had acute iliofemo-
ral DVT of native veins of which 11 were treated in a sin-
gle session and 13 in a bail-out session after incomplete 
CDT with r-tPA 20  mg over 15 hours. Sixteen patients 
(40 %) presented with iliofemoral venous stent thrombo-
sis; the index diagnosis and reason for stent implantation 
was PTS in 11 cases (69 %) and acute iliofemoral DVT in 
fi ve cases (31 %).
Procedural data
Figure 2 shows an example of venograms at baseline, after 
RT, and at completion of the procedure for the three 
groups. Primary treatment success after RT was achieved 
in 38 patients (95 %). In two patients, adjunctive CDT was 
necessary to achieve venous patency. None of the 40 pa-
tients received an IVC fi lter. Balloon angioplasty and stent 
placement was performed in all patients (mean 3.5  ±  3.2 
stents) (Table II). Among the 16 patients with stent throm-
bosis, 15 (94 %) patients had post-thrombotic venographic 
changes of the leg infl ow veins (femoral and deep femoral 
veins) at the time of the index procedure.
There were no periprocedural adverse events, such as 
arrhythmia, bleeding complications or symptomatic pul-
monary embolism. Transient macroscopic haemoglobi-
nuria during the fi rst 24 hours after intervention was re-
corded in all patients. The majority of patients received 
oral anticoagulation therapy with either direct oral antico-
agulants [n  =  31 (78 %)] or vitamin K antagonists [n  =  8 
(20 %)]. One patient with active cancer received low mo-
lecular weight heparin. Duration of oral anticoagulation 
therapy was distributed as following: for a limited period 
of three months [n = 11 (28 %)], six months [n = 3 (7 %)], 
and 12 months [n = 1 (2 %)]; and for an indefi nite period 
[n = 25 (63 %)].
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Clinical outcome during follow-up
The mean follow-up duration was 193 ± 132 days (Table II). 
For the 24 patients with iliofemoral DVT of native vessels, 
the primary patency rate was 92 % [95 % CI 75–99 %] at 
180 days (Figure 3). There was one female patient with 
metastatic bladder cancer who had right-sided iliac stent 
thrombosis at day 165, due to tumour progression with 
compression of the inferior vena cava and iliac veins. She 
underwent successful stent reconstruction of the inferior 
vena cava and iliac veins.
For the 16 patients with stent thrombosis, the primary 
patency rate was 63 % [95 % CI 35–85 %] at 180 days (Figure 
3). Six patients with an index diagnosis of PTS had sympto-
matic complete stent rethrombosis, of whom two had early 
rethrombosis within 30 days. Among the six patients, rein-
tervention was attempted in three, but not successfully.
Among the seven patients who developed symptomatic 
stent thrombosis at follow up, six (86 %) had post-thrombot-
ic venographic changes of the femoral leg infl ow veins at the 
index procedure. Among the 33 patients with patent stents 
at the latest follow-up, only nine (27 %) had post-thrombotic 
Table I. Baseline characteristicsa.
Overall (n = 40) Iliofemoral DVT (n = 24) Stent thrombosis (n = 16)
Single session (n = 11) Bail out (n = 13)
Demographics
Age, y 50.5 ± 19.5 58.8 ± 19.0 47.9 ± 18.9 46.8 ± 19.7
Women 18 (45) 5 (45) 7 (54) 6 (38)
Body mass index (kg/m2) 26.2 ± 6.0 26.9 ± 5.2 27.0 ± 3.5 25.0 ± 8.0
Venous pathology
DVT symptoms < 14 days 28 (70) 8 (73) 11 (85) 9 (56)
May-Thurner compression 12 (30) 5 (45) 3 (23) 4 (25)
Atypical iliofemoral compression 7 (18) 2 (18) 4 (31) 1 (6)
Risk factors and comorbidities
Previous DVT 19 (48) 3 (27) 2 (15) 14 (88)
Hypertension 10 (25) 4 (36) 4 (31) 2 (13)
Immobilizationb 8 (20) 3 (27) 3 (23) 2 (13)
Obesityc 10 (25) 2 (18) 4 (31) 4 (25)
Concomitant pulmonary embolism 7 (18) 2 (18) 3 (23) 2 (13)
Hormonal therapyd 7 (18) 0 5 (38) 2 (13)
Surgery and/or traumae 6 (15) 2 (18) 2 (15) 2 (13)
Smoking 8 (20) 1 (9) 1(8) 6 (38)
Active cancer or treatmentf 6 (15) 3 (27) 2 (15) 1 (6)
Known thrombophilia 3 (8) 0 0 3 (19)
Thrombus extension
Inferior vena cava 10 (25) 2 (18) 2 (15) 6 (38)
Common iliac vein 38 (95) 11 (100) 13 (100) 14 (88)
External iliac vein 40 (100) 11 (100) 13 (100) 16 (100)
Common femoral vein 40 (100) 11 (100) 13 (100) 16 (100)
Femoral vein 30 (75) 6 (55) 11 (85) 13 (81)
Popliteal vein 12 (30) 1 (9) 7 (54) 4 (25)
a: Continuous data are presented as the mean ± standard deviation, categorical data are given as numbers with percentages; b: within the previous 
three months; c: deﬁ ned as body mass index > 30 kg/m2; d: oestrogens, tamoxifen or substitute; e: within the previous four weeks; f: within the previ-
ous six months.
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venographic changes of the femoral leg infl ow veins at the 
index procedure (p = < 0.001). Among the 40 patients, there 
were no cases of asymptomatic venous restenosis.
Overall, the Villalta score at six months was 3.87 ± 5.04; 
30 patients (75 %) were free from PTS with a Villalta score 
of < 5 points (Table II). Among the 24 patients with iliofem-
oral DVT, 23 (96 %) remained free from the PTS at six 
months with a Villalta score of < 5 points. Among the 16 
patients with venous stent thrombosis, seven (44 %) were 
free from PTS at six months.
Discussion
We report the fi rst early clinical results of a novel direc-
tional RT technique for the treatment of iliofemoral DVT. 
Directional RT using the AngioJet ZelanteDVT® system 
was eff ective to restore patency in combination with bal-
loon angioplasty and venous stent placement in patients 
with iliofemoral DVT of native or stented vessels. Power-
Puls® thrombolysis was performed in 73 % patients and 
only 5 % required adjunctive CDT to achieve venous pa-
tency. Except for transient haemoglobinuria, no periproce-
dural complications occurred.
In the 24 patients with acute iliofemoral DVT of native 
vessels, six-month primary patency was 92 % and only one 
patient developed PTS. In patients with iliofemoral venous 
stent thrombosis, six-month primary patency was 63 %, 
and 56 % of the patients remained free from PTS. The 
main reason for the less favourable patency rate in patients 
with iliofemoral venous stent thrombosis was likely an im-
paired venous stent infl ow because almost all patients had 
post-thrombotic femoral veins at the index procedure. De-
spite lower patency rates, interventions for venous stent 
thrombosis should be considered because a permanently 
obstructed deep venous system may be associated with 
impaired quality of life and invalidity, leading to substan-
tial disease-related costs [18, 19].
The novel directional RT technique was specifi cally de-
signed for thrombus removal in large veins. In contrast to 
fi rst-generation RT systems, features of the novel tech-
nique include (1) a larger catheter lumen (8F instead of 
6F), (2) modifi cations at the treatment segment with one 
larger proximal suction window and one smaller distal 
outfl ow window, and (3) a rotational hub to accomplish 
directional thrombus removal (see Figure 1). The novel 
RT technique provides a strong –600  mmHg suction 
(Venturi-) eff ect at the catheter tip which is likely the rea-
son for the observed primary treatment success without 
the need for adjunctive prolonged CDT in all but two 
 patients. This clearly is an improvement when compar-
ing our results to the results of the PEARL study, in 
which 61 % of the patients treated by the fi rst-generation 
RT technique required adjunctive CDT to restore venous 
patency [13].
There is an ongoing debate whether an early revascu-
larization strategy is superior to anticoagulation thera-
py exclusively for the reduction of PTS in patients with 
acute iliofemoral DVT [20]. First results from the Acu-
te venous Thrombosis: Thrombus Removal with Adjunc-
tive Catheter-directed Thrombolysis randomized (AT-
TRACT) trial [21], which compared an early revasculari-
zation strategy to just anticoagulation therapy in 692 
patients with proximal DVT, were presented at the con-
gress of the Society of Interventional Radiology (SIR) 
in March 2017 [22]. Unfortunately, almost half of the 
 ATTRACT patients had femoropopliteal DVT without 
 involvement of the iliac veins; several thrombus remo-
val strategies were allowed and only 30 % of the patients 
had stent placement. The ATTRACT study failed to show 
that an early revascularization strategy was superior to 
just anticoagulation with similar overall PTS rates at two 
years of follow-up.
Currently, there is no evidence from randomized trials 
that RT is more eff ective than conventional CDT. It re-
Figure 2. Digital subtraction venograms.
A1: Baseline venogram from a patient with acute descending iliofemoral 
thrombosis and typical compression of the left common iliac vein; 
A2: near complete thrombus removal after single session rheolytic 
thrombectomy and PowerPuls® thrombolysis (r-tPA 10  mg); A3: ﬁ nal 
 venographic result after stent placement in common iliac vein (Sinus 
Obliquus®, Optimed, Germany); B1: venogram after failed catheter-di-
rected thrombolysis (20 mg r-tPA over 15 hours) of a patient with acute 
descending iliofemoral thrombosis and May-Thurner compression; B2: 
near complete thrombus removal after bailout rheolytic thrombectomy 
and PowerPuls® thrombolysis (r-tPA 10 mg); B3: ﬁ nal venographic result 
after stent placement in common iliac vein (Sinus Obliquus®, Optimed, 
Germany); C1: baseline venogram from a patient with acute thrombosis 
of an iliac vein stent; C2: near complete thrombus removal after rheolytic 
thrombectomy and PowerPuls® thrombolysis (r-tPA 10 mg); C3: ﬁ nal ve-
nographic result after high-pressure  balloon angioplasty of the stent.
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Table II. Procedural and clinical outcome dataa.
Overall (n = 40) Iliofemoral DVT (n = 24) Stent thrombosis (n = 16)
Single session (n = 11) Bail out (n = 13)
Follow-up
Mean follow-up, days 193 ±132 184 ± 93 220 ± 129 179 ± 160 0.65
Villalta scoreb 3.9 ± 5.0 2.3 ± 2.4 1.1 ± 1.2 6.1 ± 6.2 0.01
No PTS (< 5 points) 31 (78) 10 (91) 13 (100) 8 (50) < 0.01
rVCSS pointsc 4.2 ± 5.2 3.6 ± 4.8 1.5 ± 1.4 6.1 ± 6.2 0.04
Direct oral anticoagulants 30 (75) 9 (82) 12 (92) 9 (56) 0.07
Vitamin K antagonists 9 (23) 2 (18) 1 (8) 6 (38) 0.15
Clopidogreld 10 (25) 2 (18) 2 (15) 6 (38) 0.57
Procedural
Implanted stents 3.5 ± 3.2 2.1 ± 2.2 2.0 ± 2.3 5.7 ± 3.2 < 0.001
Stent length [mm] 241 ± 192 236 ± 227 185 ± 138 290 ± 202 0.18
PowerPuls® 29 (73) 7 (64) 7 (54) 15 (94) 0.04
Peak ﬂ ow velocitye (cm/sec) 27.7 ± 15.6 31.6 ± 20.5 30.7 ± 14.4 22.5 ± 11.9 0.28
Stent localization
Inferior vena cava 9 (18) 2 (18) 2 (15) 5 (31) 0.55
Common iliac vein 38 (95) 11 (100) 13 (100) 14 (88) 0.21
External iliac vein 36 (90) 11 (100) 11 (92) 14 (88) 0.42
Common femoral vein 25 (63) 5 (45) 5 (22) 15 (94) < 0.01
Deep Femoral vein 4 (10) 0 0 4 (25) 0.04
a: Continuous data are presented as the mean ± standard deviation, categorical data are given as numbers with percentages; b: at last follow-up; 
c: revised venous clinical severity score at last follow-up; d: for the initial three months after intervention; e: by Doppler ultrasound in the common 
femoral vein after completion of the procedure; PTS: post-thrombotic syndrome.
Figure 3. Primary patency.
Kaplan-Meier estimates 
through 180 days of pri-
mary patency rates for 40 
patients with iliofemoral 
DVT treated with directional 
rheolytic thrombectomy.
ht
tp
://
ec
on
te
nt
.h
og
re
fe
.c
om
/d
oi
/p
df
/1
0.
10
24
/0
30
1-
15
26
/a
00
06
66
 - 
Fr
id
ay
, A
pr
il 
06
, 2
01
8 
2:
35
:0
0 
A
M
 - 
U
ni
ve
rs
ity
 o
f B
er
n 
IP
 A
dd
re
ss
:1
30
.9
2.
15
.4
4 
62 J. Dopheide, T. Sebastian et al., Rheolytic thrombectomy for deep vein thrombosis
Vasa (2018), 47 (1), 56–62 © 2017 Hogrefe 
 
mains unclear whether a single-session strategy of this 
novel thrombectomy technique is eff ective and safe in pa-
tients with extensive DVT involving the popliteal and low-
er leg veins. Advantages of the novel RT technique include 
thrombus removal and provisional stent placement in a 
single session, without the need for prolonged CDT, ad-
mission to the intermediate care unit or second look ve-
nography. In contrast, CDT always requires a staged inter-
vention with catheter placement, prolonged CDT in a 
monitor unit, and second or third look venography with 
provisional stent placement.
Limitations and conclusions
Our study is limited by the relatively low number of 
study participants and short follow-ups. Nevertheless, 
our fi rst clinical results suggest that primary treatment 
success and early clinical outcomes with this novel RT 
technique are favourable for patients with iliofemoral 
DVT. Overall, RT was eff ective to restore patency in com-
bination with provisional PowerPuls® thrombolysis, bal-
loon angioplasty, and venous stent placement. The novel 
technique enables single-session DVT treatment in the 
majority of patients without the need for prolonged 
 catheter-directed thrombolysis. Future studies should 
 investigate the long-term effi  cacy and safety of this prom-
ising technique in large cohorts of patients with acute 
 iliofemoral DVT.
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